NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / World News / FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
    FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
    World

    FDA rejects emergency-use approval of Bharat Biotech's COVAXIN

    Written by Sagar
    June 11, 2021 | 02:22 pm 3 min read
    FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
    The US FDA has rejected Bharat Biotech's application for an emergency use authorization for COVAXIN.

    The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN. The authorities have asked for additional information and data for the vaccine, effectively delaying its potential launch in the US. Bharat Biotech's partner in the US says it would now seek a full approval.

    Company says it would now apply for a full approval

    The FDA has rejected the approval request as Bharat Biotech had submitted partial trial data from March this year, and data from an additional clinical trial would be required, according to Hindustan Times. Ocugen, Bharat Biotech's partner in the US, said it would skip the emergency use authorization and instead apply for a Biological License Application (BLA) or full approval at a later time.

    'Committed to bringing COVAXIN to the US'

    "The FDA provided feedback to Ocugen regarding the Master File submitted previously and recommended that we pursue a BLA submission instead of an EUA application for the vaccine candidate and requested additional information and data," Ocugen said in a statement to the New York Stock Exchange. "While this will extend our timelines, we're committed to bringing COVAXIN to the US," the company's CEO said.

    COVAXIN is 78% effective against symptomatic disease

    COVAXIN is India's only approved indigenous coronavirus vaccine. It is currently one of the three vaccines being used in India's nationwide inoculation program, that began in January. As per an interim analysis, the vaccine was found to be 78% effective against symptomatic COVID-19 disease and 100% effective in providing protection from serious illness.

    COVAXIN has not furnished phase-3 trial data yet

    The rejection from the US health officials comes at a time when Bharat Biotech is facing criticism in India for failing to share its phase-3 trial data even six months after the vaccine was granted emergency use approval in India. In January, the company had said it would submit results by March, but recently stated the data would be made public only in July.

    Many countries do not yet recognize COVAXIN

    COVAXIN has been facing troubles securing approvals in foreign countries and from the World Health Organization (WHO). International recognition is essential for the company to start widely exporting its vaccine and become part of the "vaccine passport" - under which fully vaccinated people would be allowed to travel abroad. Countries that have approved the jab include Iran, Philippines, Mauritius, Mexico, Nepal, Guyana, and Zimbabwe.

    US universities ask students who took COVAXIN to get re-vaccinated

    In fact, universities across the US are asking foreign students to get re-vaccinated if they have been inoculated with vaccines that don't yet have the approval from the WHO. This includes Indian students who may have taken COVAXIN or the Russian vaccine Sputnik V's shots.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Coronavirus
    COVAXIN

    Coronavirus

    COVID-19 'bioweapon deployed by Centre,' says filmmaker; booked for sedition Lakshadweep
    Unplanned vaccination can promote mutant strains, experts tell PM Modi India
    Severe COVID-19 requiring oxygen therapy may reduce gray matter: Study Technology
    Centre to launch nationwide campaign to counter vaccination drive rumors Mukhtar Abbas Naqvi

    COVAXIN

    After updating vaccine policy, Centre may renegotiate Covishield, COVAXIN prices Vaccine
    AIIMS-Delhi begins screening children for COVAXIN clinical trials from today All India Institute Of Medical Sciences (AIIMS)
    Deck cleared for import of COVAXIN, Sputnik V into Brazil Brazil
    COVAXIN trials on children aged 2-18 begin at AIIMS-Patna India
    Next News Article

    Love World News?

    Subscribe to stay updated.

    World Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023